Study S001944

A Randomized, Multi-dose, Controlled Trial Investigating the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01104701
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 121
Start: 2010-05
Primary completion: 2010-12
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide once weekly; DRUG:exenatide once monthly suspension
Results posted: TRUE

Registered primary outcomes

Mean Change in HbA1c From Baseline to End of Treatment (Week 20) - Evaluable Population [Baseline (Day 1) to 20 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025093	Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial. Wysham CH, Diabetes care	2016	Randomized trial	PMID 27436275 DOI	cites ClinicalTrials.gov:NCT01104701; registry reference DERIVED:27436275